Adherence to secondary preventive treatment following myocardial infarction with and without obstructive coronary artery disease

Fig 1. Study population. Patients were excluded if they did not undergo in-hospital diagnostic coronary angiography, if their result of the coronary angiography is unknown, died within 30 days after discharge, or were automatically dispensed doses of medication. Patients with previous PCI or CABG were considered to have a MI-CAD.

Fig 2. Study design. Time line demonstrating the times for initiation, implementation, and persistence of secondary preventive medications. Initiation; a filled prescription within 30 days after discharge. Persistence; the length of time between initiation and discontinuation of medical treatment (>45 days without refilled prescription). Non-persistent; patients discontinued treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. Implementation: the extent to which a patient’s actual dosing regimen corresponded to the prescribed dosing regimen.

Fig 3. Implementation of aspirin and statins as secondary preventive treatment. Implementation, e.g., the extent to which a patient’s actual dosing regimen corresponded to the prescribed dosing regimen, in patients with MINOCA and MI-CAD. A medication possession ratio (MPR) ≥ 80% was defined as high implementation.

Fig 4. Implementation of ACEI/ARB and beta blockers as secondary preventive treatment. Implementation, e.g., the extent to which a patient’s actual dosing regimen corresponded to the prescribed dosing regimen, in patients with MINOCA and MI-CAD. A medication possession ratio (MPR) ≥ 80% was defined as high implementation.

Fig 5. Persistence of treatment with aspirin and statins. Persistence; the length of time between initiation and discontinuation of medical treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort.

Fig 6. Persistence of treatment with ACEI/ARB and beta blockers. Persistence; the length of time between initiation and discontinuation of medical treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort.